近年来，在国内重要学术会议上无不谈及微创外科（技术）的问题，其中最具代表性的是中国工程院于2001年10月在北京举办的工程科技论坛“微创外科新概念”和2002年10月“中国微创外科杂志”创刊一周年大会对微创概念及相关领域技术的研讨。虽然对Minimally Invasive Procedure, Minimally Invasive Surgery, Minimal Access Surgery的中文译名和微创外科（技术）是否可以形成一个新的学科或分支学科存在着争议［1～6］，但这样的研讨却促进了我国微创外科的快速发展。现就微创概念和微创外科技术在重要领域的进展作一简单介绍。
This paper reports publication status, authors distribution and the difficulties of producing Cochrane systematic reviews （CSRs） in China to offer new ideas for further development of CSR. in China. Up to Dec. 2005, Chinese authors have published 28 CSRs （1.1%）, 10 of which were indexed by SCI.
Objective The purpose of this study, which focuses on the number of the Cochrane Systematic Review’s (CSR) full texts, protocols and registered titles from Chinese authors, is to show the development of evidence-based medicine (EBM) and promote EBM’s further development in China. Methods On the basis of The Cochrane Library (Issue 1, 2009) and the Cochrane Collaboration (March 2009) periodicals, we performed statistical analysis of different countries that released CSR’s full texts, protocols and registered titles, as well as the time, authors and distribution of the CSR’s full texts, protocols and registered titles in China. Results The publishing rates of the CSR’s full texts, protocols and registered titles in China ranked the seventh, fifth and second, respectively. Although the number of CSR’s full texts and protocols showed an increased annual trend in China, the development of area distribution was unbalanced. Moreover, China’s published articles contained 47 Cochrane collaboration groups, without effective practice and health care groups, consumers and communication groups, and methodology and multiple stenosis groups. Conclusions The current Chinese EBM situation has a great potential in writing CSR. However, there are still many problems that need to be resolved.
Objective To investigate the current status of higher education of allied health professions (AHPs), professional human resource as well as the career development of allied health professionals, and to provide references for the planning of higher education of AHPs in China. Methods Literature was reviewed in relation to the current status of higher education of AHPs and professional human resource in China. A questionnaire survey was conducted to determine the career development conditions of allied health professionals. Results a) Currently, the higher education of AHPs in China was faced with such problems as a limited scale, a lower structural level, and an absent degree system. b) The number of allied health professionals was small with lower qualifications. Higher-end professionals were in shortage. C) The professionals saw multiples glass ceilings over career orientation, academic advancement, and professional entitlement. Conclusion Efforts should be made to expand the scale of higher education of AHPs, elevate degree structure, and to construct a professional education system with multiple layers and categories. The professional education should be combined with the career development for planning and collaboration to provide assurance for the career development of the professional in China.
At the end of 2022, the National Medical Products Administration (NMPA), in conjunction with the National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College raised for the first time the important issue of clinical research globally: whether the source of the death time of clinical trials based on the simple follow-up records is credible, and proposed a consensus document on the source of the death time of clinical trials. The results were published in The Lancet Regional Health-Western Pacific, which attracted wide attention and recognition from the international industry. This is the first time that the China consensus on quality standards for clinical research has been ahead of the U.S. Food and Drug Administration and other international colleagues. The NMPA has been leading China in promoting the scientific development of clinical research, so as to constantly establish and improve the scientific regulatory system and ecological system, and promote China's full integration into the global pharmaceutical research and development system. China clinical research institutions and the whole industry are also gradually from standardized development to scientific development, high-quality development process. In this study, we summarized the scientific and subject-oriented development of China clinical research industry in recent years, and continuously strengthened the international competitiveness of China pharmaceutical industry. It is suggested that scientific thinking model should be used to deal with the normative problems in clinical research and promote the development of medical model to scientific model.
Day surgery is regarded as a breakthrough in promoting the construction of hierarchical diagnosis and treatment because of its advantages such as effectively shortening the length of hospital stay and making full use of medical resources. In order to comply with the national policies, medical development, patient needs, and other factors, as a comprehensive tertiary hospital, Zhengzhou Central Hospital Affiliated to Zhengzhou University taking regional synergy as a carrier, combining with 92 medical units, actively explores the rational flow of patients with day surgery in the region, through implementing clinical path management, controlling surgery expenses and drug and consumables proportions, purchasing medical health insurance for day surgery patients to ensure patient safety, opening a green channel for patients at the grassroots level, effectively using the medical insurance to co-ordinate funds, and rationally planning medical treatment procedures, ect.